Reports Q3 revenue $388,000 vs. $8.000 last year. “This continues to be a year of clinical execution for Keros. In the third quarter, we completed enrollment ahead of schedule in our Phase 2 TROPOS trial of cibotercept (KER-012) in patients with pulmonary arterial hypertension,” said Jasbir Seehra, chair and CEO. “This has set the stage for upcoming clinical data updates from our three clinical assets, which are expected over the next nine months.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics to Present at Guggenheim Conference
- Jefferies starts Keros with Buy, sees potential $2B in peak sales
- Keros Therapeutics initiated with a Buy at Jefferies
- Keros Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls